Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Imatinib

被引:5
|
作者
Zgolli, F. [1 ,2 ]
Aouinti, I [1 ,2 ]
Charfi, O. [1 ,2 ]
Badri, T. [2 ,3 ]
Elaidli, S. [1 ,2 ]
Kastalli, S. [1 ,2 ]
Lakhoua, G. [1 ,2 ]
Zaiem, A. [1 ,2 ]
机构
[1] Natl Ctr Chalbi Belkahia Pharmacovigilance, 9 Ave Dr Zouhaier Essafi, Tunis 1006, Tunisia
[2] Univ Tunis El Manar, Fac Med, Res Unit UR17ES12, 15 Rue Djebel Lakhdhar, Tunis 1007, Tunisia
[3] Habib Thameur Hosp, Dept Dermatol, Tunis, Tunisia
关键词
Drug hypersensitivity syndrome; DRESS syndrome imatinib; pharmacovigilance; adverse drug reaction; CML; GIST;
D O I
10.2174/1574886314666190130150243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Imatinib is the treatment of choice in patients with locally advanced or metastatic gastrointestinal stromal tumours (GIST). Clinical tolerance of imatinib is excellent except for the common adverse drug reaction (ADR). Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction, characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia, and elevated liver function tests. This ADR is rarely reported with imatinib. Only four cases of DRESS syndrome associated with imatinib have already been published. Case Report: We report an exceptional case of DRESS syndrome associated with imatinib in a 46 year-old woman with GIST. Two weeks after she had started imatinib therapy, she developed a skin rash, with eosinophilia and elevated liver tests. Plasma level of imatinib was within the therapeutic range. Imatinib was immediately discontinued. A favourable outcome was slowly observed after the drug had been stopped. Results and Conclusion: This case was scored three according to the European Registry of Severe Cutaneous Adverse Reactions Study Group (RegiSCAR). The Naranjo score for imatinib was five (probable).
引用
收藏
页码:151 / 154
页数:4
相关论文
共 50 条
  • [41] Nevirapine-induced rash with eosinophilia and systemic symptoms (DRESS)
    Gill, Shaman
    Sagar, Amitabh
    Shankar, S.
    Nair, Velu
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 (04) : 401 - 402
  • [43] Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia
    Vatel, Orlane
    Aumont, Cedric
    Mathy, Vincent
    Petit, Morgane
    Feriel, Joffrey
    Sloma, Ivan
    Bennaceur-Griscelli, Annelise
    Turhan, Ali G.
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 473 - 474
  • [45] Isoniazid-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Presenting as Acute Eosinophilic Myocarditis
    Zhang, Sai-Nan
    He, Qiu-Xiang
    Yang, Nai-Bin
    Ni, Shun-Lan
    Lu, Ming-Qin
    INTERNAL MEDICINE, 2015, 54 (10) : 1227 - 1230
  • [46] Drug rash with eosinophilia and systemic symptoms - drug-induced hypersensitivity syndrome
    Lis-Swiety, Anna
    Brzezinska-Wcisto, Ligia
    Bergler-Czop, Beata
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2010, 27 (04): : 297 - 302
  • [47] Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS)
    Wei, Chia-Hung
    Hui, Rosaline Chung-Yee
    Chang, Chee-Jen
    Ho, Hsin-Chun
    Yang, Chih-Hsun
    Lin, Yu-Jr
    Chung, Wen-Hung
    EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (06) : 930 - 937
  • [48] Temozolomide-induced drug rash with eosinophilia and systemic symptoms syndrome
    Mehta, Hitaishi
    Gendle, Chandra Shekhar
    Kumaran, Muthu Sendhil
    Vinay, Keshavamurthy
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2023, 89 (01): : 160 - 163
  • [49] A CASE OF SEVERE DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME COMPLICATING AIRWAY MANAGEMENT
    Kumar, Asheesh
    Goldfarb, Jeremy
    Bittner, Edward
    CRITICAL CARE MEDICINE, 2010, 38 (12) : U281 - U281
  • [50] Eslicarbazepine-related DRESS syndrome (drug rash with eosinophilia and systemic symptoms), a case report
    Alvarez Cabrera, R. C.
    Ordorica Lopez, R.
    Cadenas Mancenido, A.
    Pena Pardo, M. A.
    Sanchez Santiago, M. B.
    Vega Gil, N.
    Garcia Saiz, M. D. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 135 : 48 - 48